Publication Cover
Xenobiotica
the fate of foreign compounds in biological systems
Volume 52, 2022 - Issue 7
223
Views
0
CrossRef citations to date
0
Altmetric
General Xenobiochemistry

Species differences in liver microsomal hydrolysis of acyl glucuronide in humans and rats

, , , , ORCID Icon &
Pages 653-660 | Received 06 Aug 2022, Accepted 29 Sep 2022, Published online: 10 Oct 2022

References

  • Asai Y, Sakakibara Y, Kondo M, Nadai M, Katoh M. 2017. Species and tissue differences in β-estradiol 17-glucuronidation. Biol Pharm Bull. 40(10):1754–1758.
  • Bailey MJ, Dickinson RG. 1999. Limitations of hepatocytes and liver homogenates in modelling in vivo formation of acyl glucuronide-derived drug-protein adducts. J Pharmacol Toxicol Methods. 41(1):27–32.
  • Brunelle FM, Verbeeck RK. 1993. Glucuronidation of diflunisal by rat liver microsomes. Effect of microsomal beta-glucuronidase activity. Biochem Pharmacol. 46(11):1953–1958.
  • Brunelle FM, Verbeeck RK. 1996. Glucuronidation of diflunisal in liver and kidney microsomes of rat and man. Xenobiotica. 26(2):123–131.
  • Brunelle FM, Verbeeck RK. 1997. Conjugation-deconjugation cycling of diflunisal via beta-glucuronidase catalyzed hydrolysis of its acyl glucuronide in the rat. Life Sci. 60(22):2013–2021.
  • Camilleri P, Buch A, Soldo B, Hutt AJ. 2018. The influence of physicochemical properties on the reactivity and stability of acyl glucuronides. Xenobiotica. 48(9):958–972.
  • Compernolle F, Blanckaert N, Heirwegh KP. 1977. The fate of bilirubin-IXalpha glucuronides in cholestatic bile: sequential migration of the 1-acylaglycone to the 2-, 3- and 4- positions of glucuronic acid. Biochem Soc Trans. 5(1):317–319.
  • Higashi E, Ando A, Iwano S, Murayama N, Yamazaki H, Miyamoto Y. 2014. Hepatic microsomal UDP-glucuronosyltransferase (UGT) activities in the microminipig. Biopharm Drug Dispos. 35(6):313–320.
  • Inoue NR, Hall A, Lai WG, Williams ET. 2013. Reversible inhibition of human carboxylesterases by acyl glucuronides. Drug Metab Dispos. 41(4):698–703.
  • Ito Y, Fukami T, Yokoi T, Nakajima M. 2014. An orphan esterase ABHD10 modulates probenecid acyl glucuronidation in human liver. Drug Metab Dispos. 42(12):2109–2116.
  • Iwaki M, Ogiso T, Inagawa S, Kakehi K. 1999. In vitro regioselective stability of beta-1-O- and 2-O-acyl glucuronides of naproxen and their covalent binding to human serum albumin. J Pharm Sci. 88(1):52–57.
  • Iwamura A, Fukami T, Higuchi R, Nakajima M, Yokoi T. 2012. Human alpha/beta hydrolase domain containing 10 (ABHD10) is responsible enzyme for deglucuronidation of mycophenolic acid acyl-glucuronide in liver. J Biol Chem. 287(12):9240–9249.
  • Iwamura A, Ito M, Mitsui H, Hasegawa J, Kosaka K, Kino I, Tsuda M, Nakajima M, Yokoi T, Kume T. 2015. Toxicological evaluation of acyl glucuronides utilizing half-lives, peptide adducts, and immunostimulation assays. Toxicol In Vitro. 30(1 Pt B):241–249.
  • Iwamura A, Watanabe K, Akai S, Nishinosono T, Tsuneyama K, Oda S, Kume T, Yokoi T. 2016. Zomepirac acyl glucuronide is responsible for zomepirac-induced acute kidney injury in mice. Drug Metab Dispos. 44(7):888–896.
  • Jiao W, Zhao X, Wu G, Zhang X, Wu H, Cui Y. 2020. Bioactivation of lumiracoxib in human liver microsomes: formation of GSH- and amino adducts through acyl glucuronide. Drug Test Anal. 12(6):827–835.
  • Johnson G, Moore SW. 2000. Cholinesterase-like catalytic antibodies: reaction with substrates and inhibitors. Mol Immunol. 37(12–13):707–719.
  • King C, Tang W, Ngui J, Tephly T, Braun M. 2001. Characterization of rat and human UDP-glucuronosyltransferases responsible for the in vitro glucuronidation of diclofenac. Toxicol Sci. 61(1):49–53.
  • Kobayashi K, Smith JA. 1987. Acyl-peptide hydrolase from rat liver. Characterization of enzyme reaction. J Biol Chem. 262(24):11435–11445.
  • Kobayashi Y, Fukami T, Nakajima A, Watanabe A, Nakajima M, Yokoi T. 2012. Species differences in tissue distribution and enzyme activities of arylacetamide deacetylase in human, rat, and mouse. Drug Metab Dispos. 40(4):671–679.
  • Kojima A, Nadai M, Katoh M. 2022. Species and tissue differences in regorafenib glucuronidation. Xenobiotica. 52(2):129–133.
  • Lasser KE, Allen PD, Woolhandler SJ, Himmelstein DU, Wolfe SM, Bor DH. 2002. Timing of new black box warnings and withdrawals for prescription medications. JAMA. 287(17):2215–2220.
  • Levvy GA. 1952. The preparation and properties of β-glucuronidase. Biochem J. 52(3):464–472.
  • Miles KK, Stern ST, Smith PC, Kessler FK, Ali S, Ritter JK. 2005. An investigation of human and rat liver microsomal mycophenolic acid glucuronidation: evidence for a principal role of UGT1A enzymes and species differences in UGT1A specificity. Drug Metab Dispos. 33(10):1513–1520.
  • Miyake Y, Mayumi K, Jinno H, Tanaka-Kagawa T, Narimatsu S, Hanioka N. 2013. cDNA cloning and functional analysis of minipig uridine diphosphate-glucuronosyltransferase 1A1. Biol Pharm Bull. 36(3):452–461.
  • Miyashita T, Kimura K, Fukami T, Nakajima M, Yokoi T. 2014. Evaluation and mechanistic analysis of the cytotoxicity of the acyl glucuronide of nonsteroidal anti-inflammatory drugs. Drug Metab Dispos. 42(1):1–8.
  • Oda S, Fukami T, Yokoi T, Nakajima M. 2015. A comprehensive review of UDP-glucuronosyltransferase and esterases for drug development. Drug Metab Pharmacokinet. 30(1):30–51.
  • Oda S, Matsuo K, Nakajima A, Yokoi T. 2016. A novel cell-based assay for the evaluation of immune- and inflammatory-related gene expression as biomarkers for the risk assessment of drug-induced liver injury. Toxicol Lett. 241:60–70.
  • Oleson L, Court MH. 2008. Effect of the beta-glucuronidase inhibitor saccharolactone on glucuronidation by human tissue microsomes and recombinant UDP-glucuronosyltransferases. J Pharm Pharmacol. 60(9):1175–1182.
  • Regan SL, Maggs JL, Hammond TG, Lambert C, Williams DP, Park BK. 2010. Acyl glucuronides: the good, the bad and the ugly. Biopharm Drug Dispos. 31(7):367–395.
  • Sawamura R, Okudaira N, Watanabe K, Murai T, Kobayashi Y, Tachibana M, Ohnuki T, Masuda K, Honma H, Kurihara A, et al. 2010. Predictability of idiosyncratic drug toxicity risk for carboxylic acid-containing drugs based on the chemical stability of acyl glucuronide. Drug Metab Dispos. 38(10):1857–1864.
  • Schöllhammer I, Poll DS, Bickel MH. 1975. Liver microsomal beta-glucuronidase and UDP-glucuronyltransferase. Enzyme. 20(5):269–276.
  • Scialis RJ, Manautou JE. 2016. Elucidation of the mechanisms through which the reactive metabolite diclofenac acyl glucuronide can mediate toxicity. J Pharmacol Exp Ther. 357(1):167–176.
  • Shimada H, Ikuta H, Kumazawa K, Nomi M, Shiojiri M, Kawase A, Iwaki M. 2022. Relationship between the risk of idiosyncratic drug toxicity and formation and degradation profiles of acyl-glucuronide metabolites of nonsteroidal anti-inflammatory drugs in rat liver microsomes. Eur J Pharm Sci. 174:106193.
  • Shimada H, Kobayashi Y, Tanahashi S, Kawase A, Ogiso T, Iwaki M. 2018. Correlation between glucuronidation and covalent adducts formation with proteins of nonsteroidal anti-inflammatory drugs. Eur J Pharm Sci. 112:132–138.
  • Shiratani H, Katoh M, Nakajima M, Yokoi T. 2008. Species differences in UDP-glucuronosyltransferase activities in mice and rats. Drug Metab Dispos. 36(9):1745–1752.
  • Skonberg C, Olsen J, Madsen KG, Hansen SH, Grillo MP. 2008. Metabolic activation of carboxylic acids. Expert Opin Drug Metab Toxicol. 4(4):425–438.
  • Smith PC, Benet LZ, McDonagh AF. 1990. Covalent binding of zomepirac glucuronide to proteins: evidence for a Schiff base mechanism. Drug Metab Dispos. 18(5):639–644.
  • Smith PC, McDonagh AF, Benet LZ. 1986. Irreversible binding of zomepirac to plasma protein in vitro and in vivo. J Clin Invest. 77(3):934–939.
  • Soars MG, Riley RJ, Findlay KA, Coffey MJ, Burchell B. 2001. Evidence for significant differences in microsomal drug glucuronidation by canine and human liver and kidney. Drug Metab Dispos. 29(2):121–126.
  • Spahn-Langguth H, Benet LZ. 1992. Acyl glucuronides revisited: is the glucuronidation process a toxification as well as a detoxification mechanism? Drug Metab Rev. 24(1):5–47.
  • Suzuki E, Yamamura N, Ogura Y, Nakai D, Kubota K, Kobayashi N, Miura S, Okazaki O. 2010. Identification of valproic acid glucuronide hydrolase as a key enzyme for the interaction of valproic acid with carbapenem antibiotics. Drug Metab Dispos. 38(9):1538–1544.
  • Tanaka Y, Suzuki A. 1994. Enzymatic hydrolysis of zenarestat 1-O-acylglucuronide. J Pharm Pharmacol. 46(3):235–239.
  • Wong KP. 1970. A new fluorometric assay of beta-glucuronidase in tissues and serum. Anal Biochem. 35(1):35–45.
  • Xu J, Oda S, Yokoi T. 2018. Cell-based assay using glutathione-depleted HepaRG and HepG2 human liver cells for predicting drug-induced liver injury. Toxicol In Vitro. 48:286–301.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.